PMID-32127832 – Liraglutide Efficacy and Safety in Obese Non-Diabetic Individuals Meta-Analysis
Zhang P, Liu Y, Ren Y, Bai J, Zhang G, Cui Y. The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis. Afr Health Sci. 2019;19(3):2591-2599.
Quick Reference
| Property | Value |
|---|---|
| PMID | 32127832 |
| DOI | 10.4314/ahs.v19i3.35 |
| Year | 2019 |
| Journal | African Health Sciences |
| Study Type | Systematic Review and Meta-Analysis |
| Evidence Level | I |
| Sample | 6 RCTs, total n=5,218 participants |
| Peptide(s) Studied | Liraglutide |
Key Findings
- Body weight reduction: Liraglutide 3.0 mg produced significantly greater weight loss than placebo — weighted mean difference (WMD) of -5.25 kg (95% CI: -5.56 to -4.94; p<0.00001)
- BMI reduction: Significant BMI decrease with liraglutide — WMD -1.94 kg/m2 (95% CI: -2.09 to -1.78; p<0.00001)
- Waist circumference: Significant reduction — WMD -3.84 cm (95% CI: -4.38 to -3.30; p<0.00001)
- Gastrointestinal adverse events: Significantly more common with liraglutide — nausea RR 2.89 (95% CI: 2.24-3.73), diarrhea RR 1.58 (95% CI: 1.34-1.86), vomiting RR 4.17 (95% CI: 2.78-6.25)
- Serious adverse events: No significant difference between liraglutide and placebo groups
- Dose-response: 3.0 mg dose consistently superior to lower doses for weight loss in included studies
Study Design
Systematic review and meta-analysis following PRISMA guidelines. Searched PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov for RCTs comparing liraglutide to placebo in obese or overweight non-diabetic adults. Included 6 RCTs with treatment durations of 20-56 weeks. Risk of bias assessed using Cochrane Collaboration tool. Heterogeneity assessed using I-squared statistic. Random-effects model used where significant heterogeneity was detected.
Limitations
- Moderate heterogeneity in some outcomes (body weight I2=48%) likely due to varying treatment durations and doses across studies
- Limited to English-language publications, possibly introducing language bias
- Most included trials were industry-sponsored (Novo Nordisk), introducing potential funding bias
- All included studies were of relatively short duration (<=56 weeks) — long-term safety and durability not captured
- Did not stratify by comorbidity status or ethnicity
- Journal impact factor relatively low; however, methodology is sound and results align with individual trial findings
Clinical Relevance
This meta-analysis provides Level I evidence confirming the efficacy and acceptable safety profile of liraglutide 3.0 mg for weight management in non-diabetic obese individuals. The pooled -5.25 kg weight difference versus placebo is clinically meaningful and exceeds the FDA benchmark for anti-obesity pharmacotherapy. The safety profile confirms GI events as the primary tolerability concern, with no increase in serious adverse events. This evidence supports liraglutide (Saxenda) as a pharmacological option for patients who have failed lifestyle interventions alone, though the emergence of semaglutide (Wegovy) with superior weight loss efficacy (-12.4 kg vs placebo in STEP 1) has shifted first-line preferences within the GLP-1 RA class.
Related
#research #systematic-review #meta-analysis #liraglutide #evidence-level-I #metabolic